{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-030677","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.951898+00:00","generated_at":"2026-05-14T23:46:34.475558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029","bullets":["Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.","FY2026 organic growth guidance cut to -2% to +1% (prev. 3-5%); Adj. EBITDA margin now -125bps to flat.","Long-range plan extended from 2028 to 2029; B Medical Systems sale delayed due to buyer financing.","Non-GAAP diluted EPS -$0.04 vs. +$0.01 prior year; cash and securities $565M; no share repurchases yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-030677","json":"https://secwatch.observer/filing/0001628280-26-030677.json","markdown":"https://secwatch.observer/filing/0001628280-26-030677.md","text":"https://secwatch.observer/filing/0001628280-26-030677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/0001628280-26-030677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/azta-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:46:34.475558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"540b7886b92861ad72d8a377456330f42f6c3379","claim":"Azenta, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $145 million, EPS ($3.41). Guidance lowered.","evidence_excerpt":"position Azenta for improved execution, greater consistency, and profitable long‐term value creation.” Second Quarter Fiscal 2026 Results - Continuing Operations • Revenue was $145 million, up 1% year over year. Organic revenue, which excludes a 3-percentage point impact from foreign exchange and a 1-percentage point from the acquisition of UK Biocentre Limited,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/0001628280-26-030677-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2026"},{"label":"Revenue","value":"$145 million"},{"label":"EPS","value":"($3.41)"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}